Lidocaine (hydrochloride hydrate)

Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia[1][2].

Product Specifications

CAS Number

[6108-05-0]

Product Name Alternative

Lignocaine (hydrochloride hydrate)

UNSPSC

12352005

Hazard Statement

H301

Target

Apoptosis; ERK; MEK; NF-κB; Sodium Channel

Type

Reference compound

Related Pathways

Apoptosis; MAPK/ERK Pathway; Membrane Transporter/Ion Channel; NF-κB; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/lidocaine-hydrochloride-hydrate.html

Purity

99.80

Solubility

H2O : ≥ 100 mg/mL

Smiles

O=C(NC1=C(C)C=CC=C1C)CN(CC)CC.Cl.O

Molecular Formula

C14H25ClN2O2

Molecular Weight

288.81

Precautions

H301

References & Citations

[1]Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582 (Pt 1) :11.|[2]Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19 (1) :233.|[3]Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113 (1) :31-6.